MARKET

NERV

NERV

Minerva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.930
+0.250
+6.79%
Pre Market: 3.930 0 0.00% 07:05 11/24 EST
OPEN
3.660
PREV CLOSE
3.680
HIGH
3.950
LOW
3.630
VOLUME
84
TURNOVER
--
52 WEEK HIGH
15.22
52 WEEK LOW
1.810
MARKET CAP
167.71M
P/E (TTM)
-7.3184
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference
WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST). The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.About Minerva NeurosciencesMinerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.Contact:William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
GlobeNewswire · 11/09 13:30
Minerva Neurosciences share slumps despite Q3 earnings beat
Minerva Neurosciences ([[NERV]] -3.6%) Q3 loss from operations of $8.1M vs. last year's income of $14.28.Cash, cash equivalents and restricted cash as of September 30, 2020 were ~$32.6M.Research and development expenses
Seekingalpha · 11/02 16:49
Minerva Neurosciences EPS beats by $0.03
Minerva Neurosciences (NERV): Q3 GAAP EPS of -$0.19 beats by $0.03.Cash and cash equivalents of $32.5MPress Release
Seekingalpha · 11/02 12:37
Minerva Neurosciences Shares Spike Higher; Co Granted U.S. Patent Titled 'Compositions and methods for treating schizophrenia'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5&f=G&l=50&d=PTXT&S1=(20201013.PD.+AND+minerva)&OS=ISD/10/13/2020+AND+miner
Benzinga · 10/13 18:58
We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Simply Wall St. · 10/05 20:00
Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the virtual H.C. Wainwright
GlobeNewswire · 09/09 12:30
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in Citi's 15th Annual
GlobeNewswire · 09/02 12:30
Minerva Neurosciences Q2 EPS $0.75, May Not Compare To $(0.29) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $(0.29) by 358.62 percent. This is a 334.38 percent increase over losses of $(0.32) per
Benzinga · 08/03 11:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NERV. Analyze the recent business situations of Minerva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NERV stock price target is 6.90 with a high estimate of 10.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 142
Institutional Holdings: 42.27M
% Owned: 99.05%
Shares Outstanding: 42.67M
TypeInstitutionsShares
Increased
17
3.15M
New
23
1.45M
Decreased
30
2.60M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Remy Luthringer
Chief Financial Officer/Executive Vice President
Geoffrey Race
Chief Operating Officer/Senior Vice President
Joseph Reilly
Senior Vice President/Chief Accounting Officer
Frederick Ahlholm
Senior Vice President/General Counsel
Devin Smith
Senior Vice President
Jay Saoud
Other
Michael Davidson
Lead Director/Independent Director
William Doyle
Independent Director
Hans Hasler
Independent Director
Jeryl Hilleman
Independent Director
G. van Heek
Independent Director
David Kupfer
Independent Director
Fouzia Laghrissi-Thode
Independent Director
Jan van Heek
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Minerva Neurosciences Inc stock information, including NASDAQ:NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NERV stock methods without spending real money on the virtual paper trading platform.